RxDoctor Payments Data

Mohit Shukla, MD

Rheumatology · Fresh Meadows, NYNPI 1891136560

Payments from drug & device makers

$973in general payments, 2019–2025

Across 22 payments — averaging $44.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$314
  • Mallinckrodt Enterprises LLC$155
  • Amgen$141
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$134
  • Inspire Medical Systems, Inc.$108
  • Mallinckrodt Hospital Products Inc.$60
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$89492%
  • Education$808%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$973 in reported general payments places this provider in the 35th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$81,286
Medicare patients
256
Services billed
1,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab120$778,555
KevzaraSarilumab58$245,905
IlarisCanakinumab/Pf12$223,436
Enbrel SureclickEtanercept19$124,753
Orencia ClickjectAbatacept20$111,906
Taltz AutoinjectorIxekizumab11$98,344
ProliaDenosumab55$89,982
Leflunomide159$11,555
RasuvoMethotrexate/Pf11$8,287
MethotrexateMethotrexate Sodium261$8,152
Hydroxychloroquine Sulfate236$7,841
Mycophenolate Mofetil33$4,608
Gabapentin228$2,248
Diclofenac Sodium82$2,211
Duloxetine Hcl85$1,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$141$89,98255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 541 rheumatology providers in New York.

Other rheumatology in Fresh Meadows

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →